SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trialFang Zheng, Guozhong Gong, Yanwen Zhou et al.|International Journal of Infectious Diseases|2020Cited by 64
Igf2bp2 knockdown improves CCl4-induced liver fibrosis and TGF-β-activated mouse hepatic stellate cells by regulating Tgfbr1Zhenyu Xu, Feng Peng, Bo He et al.|International Immunopharmacology|2022Cited by 16
A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19Fang Zheng, Guozhong Gong, Yanwen Zhou et al.|medRxiv|2020Cited by 14
[Risk factors related to HIV new infections among men who have sex with men in a cohort study].Wei Guo, Yan Cui, Lifang Dong et al.|PubMed|2018Cited by 7
Reply to “Novaferon, treatment in COVID-19 patients”Fang Zheng, Guozhong Gong, Yanwen Zhou et al.|International Journal of Infectious Diseases|2020Cited by 2